TARO PHARMACEUTICAL INDUSTRIES LTD Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Mar 31, 2023	FY2022 12 months to Mar 31, 2022	FY2021 12 months to Mar 31, 2021	FY2020 12 months to Mar 31, 2020	FY2019 12 months to Mar 31, 2019
Sales, net
Cost of sales
Impairment
Gross profit
Operating expenses:
Research and development
Selling, marketing, general and administrative
Settlements and loss contingencies
Total operating expenses
Operating income (loss)
Financial (income) expense, net
Financial income, net
Other gain, net
Income (loss) before income taxes
Tax expense
Net income (loss)
Net loss attributable to non-controlling interest
Net income (loss) attributable to Taro
Basic and Diluted
Net income (loss) per ordinary share attributable to Taro:
Basic
Diluted
Weighted-average number of ordinary shares used to compute net income (loss) per share:
Basic
Diluted

Comments